Cell therapy is expected to relieve the shortage of donors needed for organ transplantation. When patients are treated with allogeneic or xenogeneic cells, it is necessary to develop a means by which to isolate administered cells from an immune attack by the host. We have developed "cytomedicine," which consists of functional cells entrapped in semipermeable polymer, and previously reported that alginate-poly-L-lysinealginate microcapsules and agarose microbeads could protect the entrapped cells from injury by cellular immunity. However, their ability to isolate from humoral immunity was insufficient. It is well known that the complement system plays an essential role in rejection of transplanted cells by host humoral immunity. Therefore, the goal of the present study was to develop a novel cytomedical device containing a polymer capable of inactivating complement. In the screening of various polymers, polyvinyl sulfate (PVS) exhibited high anticomplement activity and low cytotoxicity. Murine pancreatic β-cell line (MIN6 cell) entrapped in agarose microbeads containing PVS maintained viability and physiological insulin secretion, replying in response to glucose concentration, and resisted rabbit antisera in vitro. PVS inhibited hemolysis of sensitized sheep erythrocytes (EAs) and rabbit erythrocytes by the complement system. This result suggests that PVS inhibits both the classical and alternative complement pathways of the complement system. Next, the manner in which PVS exerts its effects on complement components was examined. PVS was found to inhibit generation of C4a and Ba generation in activation of the classical and alternative pathways, respectively. Moreover, when the EAC1 cells, which were carrying C1 on the EAs, treated with PVS were exposed to C1-deficient serum, hemolysis decreased in a PVS dose-dependent manner. These results suggest that PVS inhibits C1 in the classical pathway and C3 convertase formation in the alternative pathway. Therefore, PVS may be a useful polymer for developing an anticomplement device for cytomedical therapy.
INTRODUCTION
gested their possible application as a therapy for diabetes mellitus (2,5). We have attempted to develop "cytomedicine," a Organ transplantation is generally performed on panovel therapy in which long-term in vivo delivery of tients who suffer from chronic failure of a vital organ. bioactive molecules is provided by functional cells en-Although the clinical results of transplantation have been trapped in a semipermeable polymer. In our previous improved by the development of excellent immunosupresearch, we found that hybridoma cells and a pancreatic pressive drugs (26) , there still remains the urgent probβ-cell line entrapped within alginate-poly-L-lysine-algilem of a shortage of donated human organs and tissues. nate (APA) microcapsules or agarose microbeads could Cell therapy, which utilizes transplants of allogeneic or escape from recognition of the host's cellular immune xenogeneic functional cells instead of organs and tissystem and achieve long-term delivery of bioactive molsues, is one possible solution to this problem (3,13,19, ecules with therapeutic effects in allogeneic mice (15, 31) . In fact, studies of pancreatic β-cell lines have sug-788 SUZUKI ET AL. [22] [23] [24] [25] . However, we also confirmed that neither APA bituric acid, 1.82 mM sodium barbital, 1 mM MgCl 2 , 0.15 mM CaCl 2 , 0.1% gelatine, pH 7.4) for complement microcapsules nor agarose microbeads could completely protect the entrapped cells from the humoral immune assay. In some experiments, GVB containing 25 mM EDTA instead of metal ion (EDTA-GVD) or GVB con-response (25) . Because there are few functional cells derived from humans at present, xenogeneic functional taining 2.5% glucose, 2 mM MgCl 2 , and 10 mM EGTA (EGTA-Mg-GGVB) was used. cells should be considered as source of cytomedicine. For cytomedicine to develop into a viable therapy it is Measurement of Anticomplement Activity of necessary to develop a novel material that has a superior Each Polymer ability to protect xenogeneic functional cells from host Each polymer was dissolved in GVB and the solution humoral immunity.
was adjusted to pH 7.4. Polymer solutions and guinea In humoral immunity the complement system is espig serum diluted to 1/32 in GVB were mixed in a 1:1 sential for injury to transplanted non-self cells: activaratio then incubated for 1 h at 37°C. Sheep erythrocytes tion of complement is necessary for hyperacute rejection were suspended in EDTA-GVB at 1 × 10 9 cells/ml, and of xenografts (28) . Thus arose the idea to provide cyincubated for 1 h at 37°C with rabbit hemolysin (Cedartomedicine with anticomplement capabilities in order to lane Lab. Ltd., Canada) diluted to 1/500 in EDTA-GVB. isolate xenogeneic functional cells from host humoral Sheep erythrocytes sensitized with rabbit hemolysin immunity. In the present study, we initially searched for (EAs) were washed with GVB and resuspended in GVB polymers that showed high anticomplement activity and at 4 × 10 8 cells/ml. The polymer-guinea pig serum solulow cytotoxicity. The best candidate polymer was polytion, EAs suspension, and GVB were mixed in a ratio vinyl sulfate (PVS), which met both qualifications very of 1:1:4 and incubated for 1 h at 37°C. The final mixture well. Microbeads were prepared from a mixture of agarwas centrifuged and absorbance (A 541nm ) of the supernaose and PVS (agarose/PVS), and the influence of this tant was measured. Anticomplement activity of polymer novel device on viability and function of entrapped cells was calculated by the following formula: anticomplewas examined. In addition, the effect of agarose/PVS ment activity
where microbeads on humoral immunoisolation and the mech-
A is A 541nm of sample supernatant; B is A 541nm of 100% anism by which it exerted its anticomplement effects hemolysis supernatant, where all erythrocytes are lysed were examined.
in water (positive control); C is A 541nm of 0% hemolysis MATERIALS AND METHODS supernatant, where erythrocytes are incubated in buffer without complement (negative control).
Cells
We confirmed that there was no difference between The murine pancreatic β-cell line, MIN6 (16) (18) . St Louise, MO); polybrene, polyethyleneimine, polyal-Briefly, MTT solution (5 mg/ml, 10 µl) was added into lylamine, carboxymethyl cellulose, and polyacrylic acid each well and the cells were incubated at 37°C for 4 h. (Aldrich Chemical Co., Inc., Milwaukee, WI); polyeth-
The resulting formazan product was dissolved by the ylene glycol (Wako Pure Chemical Industry, Osaka, addition of 100 µl of 10% sodium dodecyl sulfate (SDS; Japan); polyvinyl sulfate (PVS) (Nacalai Tesque, Inc., Wako Pure Chemical Ind. Co., Ltd. Osaka, Japan)/15 Kyoto, Japan); polystyrene sulfonic acid (PSSa) (Toso mM HCl. The solution was read on a microplate reader Co., Yamaguchi, Japan); alginate (Kelco Co. Sandiego, at 595 nm test wavelength with a reference wavelength CA). Polyvinyl pyrrolydone was synthesized as preof 655 nm. viously reported (9).
Microencapsulation of MIN6 Cells Diluents
Complement experiments were carried out in gela-Microencapsulation of MIN6 cells within agarose microbeads was performed as previously described (8,22, tine-veronal buffer (GVB; 145 mM NaCl, 3.12 mM bar-24). We enclosed the MIN6 cells in novel microbeads leased from corresponding MIN6 cells incubated in KRB without glucose. made of the agarose and PVS (agarose/PVS) as follows. First, agarose (0.2 g) was suspended in 2.5 ml of saline Complement Assay in a 50-ml glass centrifuge tube and dissolved by auto-PVS was dissolved in GVB, and then the pH was claving. The solution was cooled and kept in a 40°C adjusted to 7.4. Various concentrations of PVS solution water bath for 5 min. PVS solution (4%, 1 ml) and
were mixed in a 1:9 ratio with normal human serum MIN6 cells (2 × 10 8 cells/ml, 500 µl), also kept at 40°C, (NHS) and incubated at 37°C for 30 min. The effect were mixed together with the agarose solution. Twenty of PVS on serum CH50 and ACH50, which show total milliliters of paraffin oil (Kanto Chemical Co., Inc., complement activity and activity of alternative pathway, Tokyo, Japan) kept at 40°C was added into the cell susrespectively, was assessed by microplate titer assay pension. The liquids were emulsified by manual shaking (10, 17) . In brief, for the CH50 assay, 25 µl of EAs (1.5 × to form agarose/PVS droplets of the appropriate size (ca. 10 8 cells/ml) in GVB was added to each well containing 300-400 mm), and the centrifuge tube was then im-75 µl of serially diluted serum samples in GVB, folmersed and gently agitated in an ice bath for 5 min to lowed by incubation at 37°C for 60 min. For the ACH50 generate the agarose/PVS microbeads. The suspension assay, 25 µl of rabbit erythrocytes (5 × 10 7 cells/ml) in was mixed with 20 ml of 0.1% polybrene solution in EGTA-Mg-GGVB was added to each well containing serum-free DMEM and immersed and gently agitated in 25 µl of serially diluted serum samples in EGTA-Mgan ice bath for 30 min. The microbeads were spun down GGVB, followed by incubation at 37°C for 60 min, and into the polybrene solution by centrifugation at 2000 addition of 50 µl of EGTA-Mg-GGVB to each well. rpm for 10 min, and then the oil phase and polybrene Then the microplate was centrifuged, and the amount of solution were removed by suction. Fresh 0.1% polyhemoglobin released into the supernatant of each well brene solution was added to the centrifuge tube again, was determined spectrophotometrically at 415 nm (MTPand the centrifuge tube was immersed in an ice bath and 32, Corona Electric, Hitachinaka, Japan). The CH50 or gently agitated for 10 min in order to form a polyion ACH50 value of each sample was calculated and excomplex between PVS and polybrene on, and just inpressed as described for the ordinary tube method. side, the microbeads. The microbeads were then washed three times with ice-cold saline. Immersing the micro-
Detection of C4a or Ba Fragment Upon Activation beads in 1% carboxymethyl cellulose solution in FCS-
of Classical or Alternative Pathway free DMEM for 15 min covered the microbeads surfaces Human γ-globulin-combined polystyrene latex (Igfurther with polyanions, thus providing anionic surface latex, RA77: Eiken Kagaku, Tokyo, Japan) and zymosan charges. The microbeads were cultured in DMEM sup-A (Nacalai Tesque Inc., Kyoto, Japan) activate the complemented 10% FCS with continuous shaking. In this plement system through the classical and alternative study, the final concentration (1% w/v) of polymer was pathways, respectively (10,29). Twenty microliters of the maximum concentration still able to form micro-PVS solution at various concentrations and 180 µl of beads.
NHS were mixed, and then 20 µl of 1% Ig-latex suspen-Comparison of Insulin Secretory Response of Free sion or 30 µl of 1% zymosan A suspension was added. and Entrapped MIN6 Cells These suspensions were incubated at 37°C for 30 min, followed by centrifugation at 15,000 rpm for 10 min. MIN6 cells (2.5 × 10 5 cells) were plated in 24-well The generation of C4a and Ba fragments was assessed plates and grown in culture medium for 3 days. The by ELISA (Assay Designs, Inc., Ann Arbort, MI) and MIN6 cells and entrapped MIN6 cells (2.5 × 10 6 cells/ Western blot, respectively. 100 µl of capsules) were first preincubated for 1 h with Krebs-Ringer bicarbonate buffer (KRB; 119 mM NaCl, EAC1 Hemolysis Assay 4.7 mM KCl, 2.54 mM CaCl 2 , 1.19 mM MgSO 4 , 1.19 mM KH 2 PO 4 , 25 mM NaHCO 3 ). After KRB was re-EAs carring complement component C1 on their surface, EAC1 cells, were prepared according to the pre-moved, each well was incubated for 2 h with 2 ml of KRB containing various concentrations of glucose. The viously described method (7,17). Five hundred microliters of EAC1 cells (1.8 × 10 8 cells/ml) in GGVB and insulin released from MIN6 cells into the supernatant was measured by insulin radioimmunoassay (insulin 500 µl of PVS solution at various concentrations were mixed and incubated at 30°C for 15 min. After washing, RIA; Amersham Pharmacia Biotech, Buckinghamshire, UK). Insulin secretory response of free and entrapped PVS-treated EAC1 cells were suspended in 500 µl of GGVB. Twenty-five microliters of PVS-treated EAC1 MIN6 cells in the presence of glucose was represented as insulin secretion ratio against basal insulin level re-cells was added to microplate wells containing 75 µl of 790 SUZUKI ET AL.
C1-deficient human serum or NHS diluted with GGVB in vitro (data not shown). However, it was necessary to ascertain whether cell functions are maintained after (1/120), followed by incubation at 37°C for 60 min. The microplate was then centrifuged, and the amount of he-encapsulation in microbeads. Therefore, we investigated whether the glucose-responsive insulin secretion of moglobin released into the supernatant of each well was determined spectrophotometrically at 415 nm (MTP-32, MIN6 cells was affected by the microencapsulating procedure ( Fig. 3) . Insulin secretion by MIN6 cells en-Corona Electric).
trapped in agarose or agarose/PVS microbeads was RESULTS maintained at basal levels at a glucose concentration be-Screening of Polymers for Anticomplement Activity low physiological levels (5 mM), and increased when glucose levels reached hyperglycemic conditions. These We first screened for polymer with potent anticompatterns of insulin secretion were similar to those of free plement activity in order to develop a novel cytomedical MIN6 cells, which had a physiological glucose sensor. material that could protect entrapped cells from host hu-This result demonstrated that the microencapsulating moral immune response. As shown in Table 1 , we examprocedure using PVS had no influence on glucose reined various nonionic, cationic, and anionic polymers sponsiveness of MIN6 cells. for anticomplement activity. After each polymer was incubated with guinea pig serum at 37°C for 1 h, the mix-Anticomplement Activity of Agarose/PVS Microbeads ture was added to EAs. The anticomplement activity of To examine the anticomplement activity of agarose/ each polymer was evaluated by degree of hemolysis in-PVS microbeads, the viability of MIN6 cells entrapped hibition ( Fig. 1) .
in conventional agarose microbeads and novel agarose/ No nonionic polymers exhibited anticomplement PVS microbeads was compared in the presence of 40% activity. In contrast, all cationic polymers inhibited rabbit anti-MIN6 cell antiserum (Fig. 4) . Agarose/PVS hemolysis of EAs in a dose-dependent manner. The ormicrobeads could completely protect MIN6 cells from der of their anticomplement activity was as follows:
injury by antiserum, whereas more than 90% of MIN6 polyethyleneimine = polyallylamine > poly-L-lysine > cells entrapped within conventional agarose microbeads polybrene > DEAE-dextran. The anionic polymers, PVS, were injured. Furthermore, damage to MIN6 cells en-PSSa, and DS (MW = 10,000), showed high anticompletrapped in conventional agarose microbeads was apparment activity, with PVS exhibiting the most potent antiently caused by complement because viability was not complement activity of all investigated polymers.
affected by addition of heat-inactive antiserum instead Cytotoxicity of Anticomplement Polymers of untreated antiserum. These results demonstrated that agarose/PVS microbeads could protect entrapped cells For use in cytomedical therapy, anticomplement from complement by their anticomplement activity. polymers should not be cytotoxic for application to cy-Agarose/PVS microbeads are a promising device for the tomedical therapy. We therefore investigated the cytodevelopment of cytomedicines that can avoid the host toxicity of polymers with anticomplement ( Fig. 2) . All humoral immune response. cationic polymers severely impaired MIN6 cells at concentrations necessary for anticomplement activity. On Inhibitory Mechanisms of PVS the other hand, anionic polymers other than PSSa on Complement Activation showed no toxicity even at 1% polymer concentration.
We examined the effect of PVS on activation of the Although PSSa is endowed with high anticomplement classical and alternative pathways of the complement activity, it dose-dependently injured MIN6 cells. Taken system (Fig. 5) . PVS decreased the hemolytic titer (CH50 together, these results and those of the previous paraand ACH50) in a dose-dependent manner. graph suggest that PVS is the most promising candidate Next, we further dissected the mechanism of PVS for preparation of anticomplement device without cytoanticomplement activity by determining which steps of toxicity.
the classical and alternative pathways were involved. As Insulin Secretion Pattern of MIN6 Cells Entrapped shown in Figure 6 , PVS dose-dependently inhibited the in Agarose/PVS Microbeads generation of C4a fragment in NHS following activation of the classical pathway by Ig-latex. This result suggests MIN6 cells are thought to be a useful cell source for cytomedical treatment of diabetes mellitus because they that PVS inhibits the classical pathway at the C4 activation step. Additionally, we examined whether PVS can secrete insulin in a physiologically regulated manner. We succeeded in preparing agarose/PVS micro-inhibited C1, which activated C4 (Fig. 7) . The inhibitory effect of PVS on C1 activity was investigated in inter-beads, and confirmed that MIN6 cells, a murine pancreatic β-cell line, entrapped in this novel device could mediate erythrocytes carrying the C1 on the surface (EAC1 cells). When EAC1 cells treated with PVS were proliferate and maintain high viability for at least 1 week Table 1 . Polymers Examined for Anticomplement Activity Figure 1 . Anticomplement activity of various polymers. Each polymer (shown in Table 1 ) was dissolved in GVB solution at several concentrations (0.2%, 0.02%, 0.002%, 0.0002%, 0.00002%). Polymer solutions (100 µl) and 100 µl of guinea pig serum diluted 1/32 were mixed and incubated at 37°C for 1 h. Then sheep erythrocytes sensitized with antibody (EAs, 8 × 10 7 cells) were added and agitated for 1 h at 37°C. After shaking samples were centrifuged and absorbance of supernatant was measured at OD 541 nm. The percent remaining cytotoxic complement activity was calculated as follows: % remaining activity = [(OD541 nm of experimental group) − (OD541 nm of negative control)]/[(OD541 nm of positive control) − (OD541 nm of negative control)] × 100. Positive control was EAs lysed in water and negative control was cells incubated with complement (−). Each data point represents the mean ± SD (n = 3). exposed to C1-deficient human serum, hemolysis sharply ment system plays a major role (28) . It is necessary to provide cytomedicines with an anticomplement system decreased in relation to PVS dose. On the other hand, EAC1 cells treated with PVS were effectively hemo-in order to treat human disorders with xenogeneic functional cells. lyzed in NHS. Furthermore, in NHS, the generation of Ba fragments following activation of the alternative There are two approaches to achieving this improvement in cytomedicine. The first approach is to insert pathway by zymosan was inhibited by PVS in a dosedependent manner (Fig. 8) . These results indicate that complement regulatory molecule genes into the xenogeneic cells entrapped in semipermeable polymer. At pres-PVS interacted with C1 to inhibit activation of the classical pathway, and inhibited formation of C3 convera-ent, some complement regulatory molecules, such as decay accelerating factor (DAF, CD55) (4), homologous tase in the alternative pathway. restriction factor (HRP, CD59) (21) , and membrane co-DISCUSSION factor protein (MCP, CD46), have been identified (30). These molecules are expressed on the surface of cells We have evaluated the effectiveness of cytomedical therapy containing functional cells entrapped in semi-to avoid injury by self-complement system, but cannot suppress activation of xenogeneic complement system permeable polymers for in vivo long-term delivery of bioactive molecules, and also studied the immunological due to their species specificity. Therefore, it is possible to give resistance against human complement to cyto-properties of cytomedicine in allogeneic and xenogeneic recipients (15, (22) (23) (24) (25) . In previous studies, we confirmed medicines containing xenogeneic cells by expressing these human-derived molecules. The second approach is that the cells entrapped in agarose microbeads or APA microcapsules were isolated from host cellular immu-to incorporate anticomplement activity into the cytomedical matrix. This approach is applicable for a wide nity, but were injured by the complement system (25). It is well known that the primary cause of xenograft variety of cells, which are sensitive to humoral immunity, because the cytomedical device has an anticomple-rejection is host humoral immunity in which the comple- ment activity. Therefore, we attempted to develop the (6, 20) . It was recently reported that biohybrid artificial organs developed with these devices are effective thera-novel device with anticomplement activity.
Various devices have been developed to enclose cells pies for organ failure in an allogeneic host, but that biohybrid artificial organs enclosing xenogeneic cells failed or tissues, including agarose microbeads (7), APA microcapsule (32), hollow fiber (11), and diffusion chamber to function, suggesting that the enclosed cells were re- Figure 3 . Glucose-stimulated insulin secretion from MIN6 cells, agarose-MIN6 cells, and agarose/ PVS-MIN6 cells. MIN6 cells (2.5 × 10 5 cells/well) were plated in 24-well culture plates and grown in culture medium for 3 days. The MIN6 cells, agarose-MIN6 cells, or agarose/PVS-MIN6 cells (2.5 × 10 6 cells/100 µl of beads) were preincubated in KRB without glucose for 1 h. This buffer was removed and cells were incubated in KRB with glucose for 2 h. The supernatants were collected and assayed for insulin production. Each data point represents the mean ± SD (n = 3). jected by the host humoral immune system (7). There material. Thus, it was necessary to find polymers with equal or greater anticomplement activity and less cyto-are a few reports describing biohybrid artificial organs that could maintain long-term functionality of entrapped toxicity than PSSa.
In the screening of various polymers, we observed cells in a xenogeneic host. Iwata et al. reported that PSSa had anticomplement activity and agarose microbe-that anticomplement activity was present mainly in polymers with a sulfo-group. Among the polymers tested, ads containing PSSa could protect the islet of Langerhans entrapped host humoral immune response (7). cationic polymers and PSSa were cytotoxic to MIN6 cells. On the other hand, anionic polymers other than However, we demonstrated that a solution containing more than 0.3% PSSa was cytotoxic to MIN6 cells, indi-PSSa exhibited no cytotoxicity. We also determined that the noncytotoxic PVS anticomplement activity was 10-cating that PSSa might be an unsuitable cytomedical fold higher than PSSa. Therefore, we attempted to
The complement system is composed of up to 20 design a novel cytomedical device that was able to poplasma proteins. The system can be activated via the tently inactivate complement. The procedure for encapclassical or the alternative pathway, both of which trigsulating cells within agarose/PVS microbeads was optiger activation of the common terminal pathway. The mized and entrapped MIN6 cells showed a physiological anticomplement mechanisms of a variety of agents have insulin secretion in response to glucose concentration.
been reported by a number of researchers. FUT-175 (1), These cells were also well protected against treatment K76-COOH (14), and soluble complement receptor type with xenogeneic antisera. These results suggest that 1 inhibit the complement-activating pathway by enzyagarose/PVS microbeads can inactivate complement matic reaction (28) . Cobra venom factor consumes components while not altering cell function. complement proteins acting as complement activators, resulting in inhibition of the complement-activating pathway (12). PSSa interacts with the complement components factor H and factor D (7,27), while dextran sulfate interacts with the C1 inhibitor (33) . As demonstrated above, the anticomplement mechanism differs greatly among agents. Therefore, we chose to investigate the anticomplement mechanism of PVS. PVS decreased CH50 and ACH50 levels in a dose-dependent manner when incubated in NHS, suggesting that PVS suppresses the advance of complement activation in both classical and alternative pathways. C3 activity did not changed and C3c, which is a by-product of complement activation, was not detected in NHS after treatment with PVS (data not shown). On the basis of these data, we believe that the anticomplement mechanism of PVS was not C3 Figure 7 . Effect of PVS on C1 activity. EAC1 cells were inconsumption, which resulted from excess activation of cubated with PVS at 30°C for 30 min. After thorough washing, the complement system, and inhibition of factor H and EAC1 cells were exposed to C1-deficient human serum (᭺) or normal human serum (■).
factor I, which acted as complement regulatory factor, it is necessary to isolate them from the host immune 
